Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
Completed · Phase 2
Conditions studied: Melanoma
In brief
The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
Key facts
- Study ID
- NCT03484923
- Run by
- Novartis Pharmaceuticals
- People needed
- 196
- Starts
- 2018-09-10
- Expected to finish
- 2022-12-30
- Last updated by the study team
- 2024-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- The Angeles Clinic and Research Institute — Los Angeles, California, United States
- University of California Los Angeles — Los Angeles, California, United States
- UCSF Medical Center . — San Francisco, California, United States
- Massachusetts General Hospital Massachusetts Gen. Hospital CC — Boston, Massachusetts, United States
- NYU Laura and Isaac Perlmutter Cancer Center Perlmutter Cancer Center — New York, New York, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- Novartis Investigative Site — North Sydney, New South Wales, Australia
- Novartis Investigative Site — Westmead, New South Wales, Australia
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Montreal, Quebec, Canada
- Novartis Investigative Site — Marseille, France
- Novartis Investigative Site — Paris, France
- Novartis Investigative Site — Villejuif, France
- Novartis Investigative Site — Dresden, Germany
- Novartis Investigative Site — Essen, Germany
- Novartis Investigative Site — Hamburg, Germany
- Novartis Investigative Site — Kiel, Germany
- Novartis Investigative Site — München, Germany
- Novartis Investigative Site — Bergamo, BG, Italy
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Naples, Italy
- Novartis Investigative Site — Amsterdam, Netherlands
- Novartis Investigative Site — Rotterdam, Netherlands
- Novartis Investigative Site — Barcelona, Catalonia, Spain
- Novartis Investigative Site — L'Hospitalet de Llobregat, Catalonia, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.